CSF1R blockade improves clinical parameters in prediabetic rhesus macaques

Abstract It is unknown whether dysregulated CSF1R himonocytes/macrophages drive the progression to diabetes and if their removal endogenous replacement with fresh macrophages resolves disease. Therefore, we hypothesize that depletion of activated CSF1R+ tissue using a monoclonal antibody against freshly differentiated will alleviate inflammation in tissues ameliorate diabetes-associated disease prediabetic rhesus macaques. We identified 6 aged Indian macaques heightened fasting blood glucose as well higher area-under-the-curve an intravenous tolerance test (IVGTT), indicating prediabetes. Three animals were treated IgG1 recombinantanti-CSF1R administered i.v. (15 mg/kg) once every two weeks for weeks. An control was remaining 3 animals. Clinical parameters such pressure, plasma levels total cholesterol, glucose, insulin, adiponectin, colony stimulating factor 1 (CSF1), IL1β, monocyte chemoattractant protein (MCP-1) monitored throughout treatment up 8 after rdinjection. A 27-color flow cytometry panel used monitor changes immune cell populations study. Treatment anti-CSF1R resulted decreased increased CSF1, IL1β Flow experiments confirmed CD16+ monocytes (known be +) improvement multiple clinical associated type-2 mellitus.